Tandem Diabetes Care Files 8-K Report

TL;DR

Tandem Diabetes Care filed a routine 8-K, no major news.

AI Summary

On May 9, 2025, Tandem Diabetes Care, Inc. filed an 8-K report. The filing primarily concerns the company's current status and does not disclose specific new material events, financial figures, or executive changes in the provided text.

Why It Matters

This filing indicates Tandem Diabetes Care is adhering to its reporting obligations with the SEC, though no new material information is immediately apparent from the provided text.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without any disclosed negative events or significant changes.

Key Players & Entities

• Tandem Diabetes Care, Inc. (company) — Registrant
• May 9, 2025 (date) — Date of earliest event reported
• 12400 High Bluff Drive (location) — Principal executive offices address
• San Diego, California (location) — Principal executive offices location
• 92130 (location) — Principal executive offices zip code

FAQ

From the Filing

0001438133-25-000072.txt : 20250512 0001438133-25-000072.hdr.sgml : 20250512 20250512171649 ACCESSION NUMBER: 0001438133-25-000072 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250509 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250512 DATE AS OF CHANGE: 20250512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TANDEM DIABETES CARE INC CENTRAL INDEX KEY: 0001438133 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 204327508 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36189 FILM NUMBER: 25936030 BUSINESS ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 BUSINESS PHONE: 858-366-6900 MAIL ADDRESS: STREET 1: 12400 HIGH BLUFF DRIVE CITY: San Diego STATE: CA ZIP: 92130 8-K 1 tndm-20250509.htm 8-K tndm-20250509 0001438133 FALSE 0001438133 2025-05-09 2025-05-09   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 8-K ____________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 ____________________________ Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter) ____________________________ Delaware 001-36189 20-4327508 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer  Identification No.) 12400 High Bluff Drive 92130 San Diego California (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 858 )  366-6900 N/A (Former name or former address, if changed since last report) ____________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share TNDM NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ____________________________ Item 8.01 . Other Items On May 9, 2025, SteadiSet Infusion Set (SteadiSet) received 510(k) clearance from the United States Food and Drug Administration (FDA) for up to three days of use. SteadiSet is a wearable infusion set that delivers insulin from an insulin pump to the body and features an integrated inserter with a hidden needle designed for one-handed insertion. SteadiSet is designed to provide adult patients with Type 1 diabetes continuous insulin delivery during the indicated use period. The submission was made by Capillary Biomedical, LLC (CapBio), a wholly owned subsidiary of Tandem Diabetes Care, Inc. (the Company). The